Navigation Links
Torax Medical Launches Pivotal Clinical Study of New Acid Reflux Treatment

ST. PAUL, Minn., April 3 /PRNewswire/ -- Torax Medical Inc., a medical device company focused on the minimally invasive treatment of gastroesophageal reflux disease (GERD) has commenced a pivotal clinical trial of its LINX(TM) Reflux Management System. The trial, which is being conducted at 15 leading academic and private medical centers in the U.S. and Europe, will evaluate the safety and effectiveness of the LINX System in patients suffering from GERD despite medical therapy.

GERD is caused by a defective lower esophageal sphincter, a ring-like muscular valve that surrounds the esophagus. When defective, it allows abnormal reflux of stomach acids and bile into the esophagus. Approximately 19 million adults in the U.S. suffer on a daily basis from the symptoms of GERD. Medical therapy, such as the daily use of proton pump inhibitors (PPIs), may improve heartburn symptoms but it does not address the mechanically defective sphincter, allowing gastric reflux to continue. Chronic gastric reflux may lead to numerous complications including ulcerations and esophageal cancer. The incidence of esophageal cancer is rising at a faster rate than any other cancer in the U.S.

Robert Ganz, M.D. of Minnesota Gastroenterology and a Principal Investigator in the trial shared these comments, "Many people who suffer from GERD do not get complete relief of symptoms with drug therapy. The LINX System is intriguing because it may provide both symptom relief and correction of the physiologic defect."

The LINX Reflux Management System is intended to restore the normal barrier function in the esophagus for patients who suffer from GERD and is designed to be an outpatient, minimally invasive procedure. The device is implanted laparoscopically, with the patient likely to resume normal activities and diet at discharge. In addition to its therapeutic benefits, Torax Medical anticipates that the LINX System will have the potential to eliminate the burdens associated with lifelong drug therapy and the typical complications associated with conventional surgical repair.

Todd Berg, President and CEO of Torax Medical, considers the LINX System a promising advancement for the treatment of GERD, "We believe the simplest approach to treating GERD is to augment the body's existing sphincter so that it can function normally. Excellent clinical results were achieved in feasibility trials with the LINX System and we expect these positive clinical outcomes to continue in this Pivotal Trial".

To learn more about the study and to determine if you qualify as a candidate, visit or call 1-888-978-8391.

The LINX Reflux Management System is an investigational device and is limited by Federal U.S. law to investigational use only and is not available for sale.

About Torax Medical

Torax Medical Inc. is a privately held medical device company focused on the minimally invasive treatment of gastro-esophageal reflux disease. Its platform technology utilizes magnetic attraction forces to augment the body's sphincter anatomy. For more information, please visit

SOURCE Torax Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
2. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
3. Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial
4. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
6. Premier Research Expands its Medical Device Operations to the United States
7. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
8. Dermatologists Caution That Severe Cases of Psoriasis Can Be Associated With Other Serious Medical Conditions
9. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
10. Impact Medical Solutions Announces Initiation of Pilot Clinical Trial and Listing on Frankfurt Stock Exchange
11. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
Post Your Comments:
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
(Date:12/1/2015)... Dec. 1, 2015  Six months of adjunctive metformin therapy ... 1 diabetes, according to new research from T1D Exchange ... may have a beneficial effect on measures of obesity, including ... of the Journal of the American Medical Association , ... effect of metformin on overweight and obese adolescents with type ...
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... of non-traumatic limb amputations in the United States. Podiatrists are well aware that ... to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Center of Excellence (BHCOE) today announced that the organization has awarded Education and ... Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers that ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
(Date:12/1/2015)... Beverly Hills, CA (PRWEB) , ... December 01, ... ... honored by Modern Luxury’s Angeleno Magazine as a Modern Man for 2015. ... luxury lifestyle publisher in the United States. Established in 1994, Modern Luxury includes ...
Breaking Medicine News(10 mins):